McNeil

McNeil is a long-established consumer-healthcare business whose roots reach back to McNeil Laboratories, founded by Robert McNeil in Philadelphia in 1879. The business developed from a pharmacy and pharmaceutical operation into a manufacturer and marketer of over-the-counter medicines, with particular strength in pain relief, fever reduction, allergy treatment, gastrointestinal care, and related household health categories. McNeil became closely associated with Johnson & Johnson after Johnson & Johnson acquired McNeil Laboratories in 1959. Under Johnson & Johnson, the McNeil name was used for a consumer-healthcare operating organization rather than as a single mass-market product label. The business managed or supported a portfolio of widely distributed brands, including Tylenol acetaminophen products, Motrin ibuprofen products, Benadryl allergy products, and, in relevant markets, other over-the-counter medicines. Product ownership, licensing, manufacturing, and branding arrangements have varied by country and over time, so the presence of a particular product under the McNeil name should not be assumed to be globally uniform. The company’s best-known commercial success was the expansion of Tylenol into one of the world’s most recognized nonprescription pain-relief brands. McNeil also helped establish the broader consumer-health model in which pharmaceutical research, regulatory compliance, mass retail distribution, physician recommendation, and consumer advertising were combined. Its products have traditionally been sold through pharmacies, supermarkets, mass merchants, convenience outlets, and healthcare channels. McNeil’s history also includes significant product-quality and regulatory challenges. A series of recalls beginning in 2009 and continuing through the early 2010s affected multiple products and manufacturing operations. These actions involved issues such as manufacturing-process deviations, potential contamination concerns, and quality-control failures. The recalls damaged confidence in the affected products and led to manufacturing remediation, regulatory scrutiny, and changes in quality systems. They are an important part of the company’s history because they shaped both the McNeil operating model and expectations for quality assurance across Johnson & Johnson’s consumer-health activities. Johnson & Johnson reorganized its consumer-health activities during the 2010s, and its consumer brands were subsequently separated into Kenvue, which became an independent publicly traded company in 2023. As a result, the corporate ownership and legal structure associated with McNeil products can differ depending on the market, date, and specific product. McNeil is therefore best understood as a historical and operating consumer-health name within the Johnson & Johnson consumer portfolio and, for relevant current operations, the Kenvue consumer-health group, rather than as an independent listed company. Because the supplied name is not tied to a single clearly identified legal entity or country-specific operating company, this dossier retains a review flag.

McNeil's documented roots begin in 1879, when Robert McNeil established a pharmaceutical business in Philadelphia. The company initially operated in a traditional pharmacy and pharmaceutical environment, but over time it developed into a manufacturer and marketer of medicines intended for both professional and consumer use. A decisive turning point came in 1959, when Johnson & Johnson acquired McNeil Laboratories. The acquisition gave McNeil access to a much larger healthcare organization, broader manufacturing capabilities, and an international commercial network. McNeil subsequently became associated with Johnson & Johnson's consumer-health activities, while individual products were marketed under their own brand identities. This structure helped separate the corporate operating name from the names most visible to consumers. Tylenol became the central example of McNeil's consumer-health success. Acetaminophen products were positioned for pain and fever relief and were distributed through pharmacies, supermarkets, and other retail channels. McNeil also became associated with other major over-the-counter categories, including ibuprofen-based pain relief under Motrin and allergy products sold under names such as Benadryl and Zyrtec in applicable markets. The portfolio and legal ownership of these names have not been identical in every country. The business faced a major quality crisis from 2009 onward. Recalls involving children's and adult liquid medicines, followed by additional product actions, brought attention to manufacturing conditions, contamination risks, testing procedures, and the adequacy of quality-control systems. Regulators and the company undertook investigations and remediation, and several facilities experienced interruptions or restrictions while processes were reviewed. The episode affected the availability and reputation of important products and became a prominent case study in pharmaceutical manufacturing governance. During the 2010s, Johnson & Johnson continued to reorganize and consolidate its consumer-health operations. McNeil remained part of the wider consumer-health portfolio, but product management and operating structures evolved across regions. In 2023, Johnson & Johnson separated its consumer-health business into Kenvue, creating an independent company that owned or operated many of the consumer brands previously associated with Johnson & Johnson. The practical relationship between McNeil, Kenvue, Johnson & Johnson, and particular products therefore depends on the market and the date being examined. Today, McNeil should not be treated as a standalone publicly listed company. It is a consumer-health operating and historical name connected with a portfolio of over-the-counter medicines. Because the supplied record does not identify a specific national legal entity, the exact current status of the McNeil name requires market-specific verification.

1. 2023Consumer-health separation into Kenvue

   Johnson & Johnson completed the separation of its consumer-health business into Kenvue, changing the corporate setting for brands historically associated with McNeil.

   Source
2. 2010Broad recall of liquid medicines

   A broad recall affected certain children's and adult liquid medicines manufactured at McNeil facilities.

   Source
3. 2009Beginning of major product recalls

   McNeil began a prolonged period of product recalls and manufacturing reviews involving several over-the-counter medicines.

   Source
4. 1959Acquisition by Johnson & Johnson

   Johnson & Johnson acquired McNeil Laboratories, bringing the company into its broader healthcare and consumer-products organization.

   Source
5. 1879Robert McNeil establishes the pharmaceutical business

   Robert McNeil founded the business that became McNeil Laboratories in Philadelphia, establishing the origin of the McNeil consumer-health organization.

   Source

Mass-market, pharmacy-oriented consumer healthcare focused on trusted over-the-counter medicines, pain relief, fever reduction, and allergy care.

• TylenolPain relief and fever reduction

  Tylenol is the principal consumer brand associated with McNeil and is used for acetaminophen-based pain relief and fever reduction. The line has included products for adults, children, and different dosage formats. Formulations, packaging, and ownership arrangements vary by market.

• MotrinPain relief and fever reduction

  Motrin is an ibuprofen-based over-the-counter pain-relief and fever-reduction brand historically associated with McNeil. Its portfolio has included adult and children's formats, with market-specific formulations and distribution.

• BenadrylAllergy and antihistamine medicine

  Benadryl is an antihistamine and allergy-care brand that has been part of the Johnson & Johnson consumer-health portfolio in relevant markets. Products and ownership can differ by geography, and the name may cover more than one formulation or indication.

• ZyrtecAllergy medicine

  Zyrtec is an allergy-relief brand associated with the consumer-health portfolio historically managed within Johnson & Johnson and later Kenvue. It is sold in market-specific formulations and channels.

• 2023Separation of consumer health into KenvueStrategy

  Johnson & Johnson sought to create a separately managed company focused on consumer-health brands.

  What changed. The consumer-health business was separated from Johnson & Johnson and operated as Kenvue.

  Aftermath. The corporate ownership and operating context for consumer businesses historically associated with McNeil shifted from Johnson & Johnson to Kenvue, subject to country-specific arrangements.

  Source
• 2010Manufacturing remediation after product recallsOther

  Recalls involving several liquid medicines raised concerns about manufacturing conditions, quality controls, and testing processes.

  What changed. McNeil and Johnson & Johnson recalled affected products, reviewed manufacturing operations, and pursued corrective actions with regulatory authorities.

  Aftermath. Product availability was disrupted, regulatory scrutiny increased, and quality assurance became a central issue for the consumer-health organization.

  Source
• 1959Johnson & Johnson acquires McNeil LaboratoriesM&A

  McNeil had developed from a Philadelphia pharmaceutical business into a larger medicines company, making it a strategic fit for Johnson & Johnson's healthcare portfolio.

  What changed. Johnson & Johnson acquired McNeil Laboratories and integrated it into the wider company while retaining McNeil as an operating identity.

  Aftermath. The acquisition provided a corporate platform for McNeil's later consumer-health expansion and connected its products to Johnson & Johnson's international organization.

  Source

• 2023Johnson & Johnson completes separation of consumer-health business into Kenvue

  Johnson & Johnson completed the separation of its consumer-health business into Kenvue. The transaction changed the corporate context for consumer brands and operating businesses historically associated with McNeil.

  M&AOther
  Source
• 2011McNeil Consumer Healthcare recalls additional products during manufacturing-quality review

  Additional recalls and manufacturing actions continued as McNeil and Johnson & Johnson addressed quality-system deficiencies at facilities producing over-the-counter medicines. The events prompted continued regulatory attention and remediation work.

  RecallRegulationOther
  Source
• 2010Johnson & Johnson recalls certain liquid medicines made at McNeil facilities

  Johnson & Johnson announced a broad recall involving certain children's and adult liquid medicines manufactured by McNeil Consumer Healthcare. The action followed concerns about manufacturing conditions and product-quality controls and became one of the most consequential events in McNeil's modern history.

  RecallRegulationOther
  Source

1. McNeil Consumer Healthcare
2. U.S. Food and Drug Administration: Drug Safety and Availability
3. Kenvue: Our Company
4. Broad recall of liquid medicines